Informationen über den produzenten
|
.
Boost Exercise ToleranceA Major Breakthrough in FitnessSR9009 CAS:137986-29-9, CAS: 1379686-30-2 Synonyms: Ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylateMolecular Formula: C20H24ClN3O4SMolecular Weight: 437.94Purity: 99%Appearance: White powderSolubility: DMSODose: Dosages of 20-100mg a day have been reported by users without any negative side effects. From the information we have received, results from SR9009 treatment appear to be dose dependent up to a maximum dosage of 100mg per day. After this dosage, results tend to taper off.Application: SR9009 increase exercise endurance and loss weight.Introduction : SR9009, which is currently under development at The Scripps Research Institute (TSRI), increases the level of metabolic activity in skeletal muscles of mice. Treated mice become lean, develop larger muscles and can run much longer distances simply by taking SR9009, which mimics the effects of aerobic exercise. If similar effects can be obtained in people, the reversal of obesity, metabolic syndrome, and perhaps Type-II diabetes might be the very welcome result.The drug was developed by Professor Thomas Burris, who found that it was able to reduce obesity in populations of mice. It binds to and activates a protein called Rev-ErbAα, which influences fat and sugar burning in the liver, production of fat cells, and the body's inflammatory response.SR9009 is a research drug that was developed by Professor Thomas Burris of the Scripps Research Institute as an agonist ofRev-ErbA (i.e., increases the constitutive repression of genes regulated by Rev-ErbA)with a half-maximum inhibitory concentration (IC50) = 670 nM for Rev-ErbAα and IC50 = 800 nM for Rev-ErbAβ. Activation of Rev-erb-α by in mice SR9009 increases exercise capacity in mice by increasing mitochondria in skeletal muscle.Standard:USP
|
Hilfe
Zu Favoriten 
Dem Warenkorb hinzugefügte Favoriten
